Literature DB >> 12573788

Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer.

Rainer Görges1, E G Eising, D Fotescu, K Renzing-Köhler, A Frilling, K W Schmid, A Bockisch, O Dirsch.   

Abstract

OBJECTIVE: Ultrasonography is an established diagnostic modality in the follow-up of thyroid cancer. Color flow Doppler has been proposed by some authors as an additional tool for differentiating benign from malignant cervical lesions in various types of head and neck cancer. Over the last few years, a new generation of high-resolution ultrasound platforms with the "power-mode" feature has become available, that also enables the imaging of small vessel blood flow. The objective of our study was to find ways of optimizing the differentiation of benign and malignant cervical tumors in thyroid cancer follow-up by means of sonography.
METHODS: Hundred and twelve cervical lesions in 90 patients with thyroid cancer were evaluated by high-end ultrasonography (Sonoline Elegra, Siemens) using a small-part transducer (7.5 L 40, Siemens). B-mode sonography was performed at a frequency of 8 MHz. The Solbiati index (SI= ratio of largest to smallest diameter), configuration, echogenicity, intranodular structures, and margins were assessed. Perinodular and intranodular blood flow was evaluated by color flow Doppler (PRF 1250 Hz for conventional color flow Doppler, 868 Hz for power-mode Doppler). Possible malignancy was validated by histology, cytology, scintigraphy, and follow-up. Thirty five lesions were benign (diameter 0.4-3.0 cm) and 77 were malignant (0.4-5.4 cm). The patients were randomized into a test group and a learning group to determine the diagnostic value of various ultrasound criteria by means of statistical analysis. In the learning group, decision rules based on the dichotomized criteria were developed using a logistic regression model. Sensitivity and specificity of these decision rules were then evaluated in the test group.
RESULTS: The presence of an echocomplex pattern or irregular hyperechoic small intranodular structures (criterion A) and the presence of an irregular diffuse intranodular blood flow (criterion B) are the best indicators of malignancy, whereas an SI >>2 is highly indicative of benign changes. Color flow Doppler is a useful addition to B-mode scanning for distinguishing benign and malignant neoplasms in the follow-up of thyroid cancer. Power-mode Doppler sonography significantly improves imaging of perinodular and intranodular blood flow when compared with conventional color flow Doppler.
CONCLUSION: We propose the following decision rules based on a combination of the criteria above: (A) and (B) fulfilled: malignant, if SI< or =4; (B) but not (A) fulfilled: malignant, if SI< or =3; (A) but not (B) fulfilled: malignant, if SI< or =2; neither (A) nor (B) fulfilled: malignant, if SI approximately equal to 1 (sensitivity: 90%; specificity: 82%; accuracy 88%).

Entities:  

Mesh:

Year:  2003        PMID: 12573788     DOI: 10.1016/s0929-8266(02)00073-3

Source DB:  PubMed          Journal:  Eur J Ultrasound        ISSN: 0929-8266


  10 in total

Review 1.  [Clinical importance of thyroid gland cytology].

Authors:  S Ting; S Synoracki; A Bockisch; D Führer; K W Schmid
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

Review 2.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

3.  Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.

Authors:  L S Freudenberg; G Antoch; A Frilling; W Jentzen; S J Rosenbaum; H Kühl; A Bockisch; R Görges
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

4.  Contrast-enhanced ultrasound (CEUS) facilitated US in detecting lateral neck lymph node metastasis of thyroid cancer patients: diagnosis value and enhancement patterns of malignant lymph nodes.

Authors:  Dapeng Xiang; Yurong Hong; Bo Zhang; Pintong Huang; Guogang Li; Ping Wang; Zhiyu Li
Journal:  Eur Radiol       Date:  2014-07-09       Impact factor: 5.315

5.  American Thyroid Association statement on preoperative imaging for thyroid cancer surgery.

Authors:  Michael W Yeh; Andrew J Bauer; Victor A Bernet; Robert L Ferris; Laurie A Loevner; Susan J Mandel; Lisa A Orloff; Gregory W Randolph; David L Steward
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

6.  The sonographic characteristics of nontuberculous mycobacterial cervicofacial lymphadenitis in children.

Authors:  Jerome A Lindeboom; Anne M J B Smets; Ed J Kuijper; Rick R van Rijn; Jan M Prins
Journal:  Pediatr Radiol       Date:  2006-08-12

7.  Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.

Authors:  Lutz Stefan Freudenberg; Walter Jentzen; Thorsten Petrich; Cornelia Frömke; Robert J Marlowe; Till Heusner; Wolfgang Brandau; Wolfram H Knapp; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-27       Impact factor: 9.236

8.  Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

Authors:  L S Freudenberg; G Antoch; W Jentzen; R Pink; J Knust; R Görges; S P Müller; A Bockisch; J F Debatin; W Brandau
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

9.  Positive central lymph-nodes are underdiagnosed in patients with Bethesda V cytology in an endemic goiter region.

Authors:  Lindsay Hargitai; Stephanie Strobl; Oskar Koperek; Susanne Urach; Wolfgang Raber; Anton Staudenherz; Christian Scheuba; Philipp Riss
Journal:  Gland Surg       Date:  2020-04

10.  Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy?

Authors:  Lindsay Brammen; Martin B Niederle; Philipp Riss; Christian Scheuba; Andreas Selberherr; Georgios Karanikas; Gerd Bodner; Oskar Koperek; Bruno Niederle
Journal:  Ann Surg Oncol       Date:  2018-10-10       Impact factor: 5.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.